Table I.
Number of patients with chronic plaque psoriasis being treated with biologic therapy or subjects of the general population of Veneto, Lombardy, Emilia Romagna, and Piedmont hospitalized for or died from COVID-19 from February 20 to May 1, 2020
| Parameter, n (%) | Patients with psoriasis | General population (18+ y) | SIR (95% CI) | P value∗ |
|---|---|---|---|---|
| Number (patient-months) | 6,501 (15,378.5) | 19,978,806 (47,260,897.6) | — | — |
| Outcome measure | ||||
| Subjects positive for SARS-CoV-2 (IR, 95% CI) | † | 144,909 (30.7, 30.5-30.8) | — | — |
| Hospitalized for COVID-19 (IR, 95% CI) | 18 (11.7, 7.2-18.1) | 68,099 (14.4, 14.3-14.5) | 0.94 (0.57-1.45) | .82 |
| Deaths for COVID-19 (IR, 95% CI) | 2 (1.3, 0.2-4.3) | 22,013 (4.7, 4.6-4.7) | 0.42 (0.07-1.38) | .19 |
| Demography | ||||
| Sex: male, n (%) | 3,616 (55.6) | 9,649,834 (48.3) | — | <.001 |
| Age (y), mean ± SD | 53.4 ± 11.0 | 52.3 ± 20.0 | — | <.001 |
| <65, n (%) | 5,071 (78.0) | 14,403,251 (72.1) | 0.68 (0.30-1.35)‡ | .31 |
| ≥65, n (%) | 1,430 (22.0) | 5,575,555 (27.9) | 1.06 (0.56-1.85)‡ | .80 |
| Comorbidity, n (%) | ||||
| Obesity | 1,633 (25.1) | 2,081,748 (10.4) | — | <.001 |
| Hypertension | 2,012 (30.9) | 4,261,658 (21.3) | — | <.001 |
| Diabetes mellitus | 854 (13.1) | 1,124,563 (5.6) | — | <.001 |
| Psoriatic arthritis | 1,865 (28.7) | — | — | — |
| Biologic therapy, n (%) | ||||
| TNF-α inhibitors | 2,106 (32.4) | — | 1.02 (0.41-2.12)‡ | .91 |
| IL-17 inhibitors | 2,486 (38.2) | — | 0.80 (0.32-1.67)‡ | .62 |
| IL-12/IL-23 inhibitors | 1,691 (26.0) | — | 0.98 (0.36-2.17)‡ | 1 |
| IL-23 inhibitors | 218 (3.3) | — | 1.45 (0.07-7.16)‡ | .65 |
IR, Incidence rate × 10,000 person-months.
Data of subjects hospitalized for or died from COVID-19 in the general population are from the Civil Protection Official Repository6 and from the National Health Institute (ISS).7
Data of patients with psoriasis hospitalized for or died from COVID-19 are from electronic medical records of the participating hospitals (accessed May 1, 2020).
Data of comorbidities in the general population are from Istituto Nazionale di Statistica multipurpose survey 2019.8
Exact mid-p test was reported for SIR. Pearson χ2 test and 2-sample t test were used for the comparison of nominal and continuous variables between groups.
Asymptomatic individuals were not tested, and so the true number of COVID-19–positive patients is unknown.
SIR for COVID-19 hospitalization was reported.